You know Covance as one of the most highly regarded CROs in the world. But, did you know that Covance is a clinical trial technology provider? Covance has developed a completely agnostic software product, the Xcellerate® Informatics Suite, designed to provide you with the kind of insights into your data that can help you gain better efficiencies in your clinical trials. Eli Lilly has been one of the first major pharmaceutical companies to recognize that the future of clinical trials hinged on their ability to leverage the most advanced informatics solutions. The right informatics solutions allow a sponsor to not just manage the increasing volume of data within a trial but to increase operational visibility and derive valuable insights across their entire portfolio.
Join us for an informational webinar, where we will discuss how by using Xcellerate, you can:
- Increase transparency of data
- Improve efficiencies and consistency of procedures
- Reduce cost and complexity, and maintain high quality standards.
We will be joined by an Eli Lilly Risk Based Monitoring expert who will discuss how an Xcellerate unified monitoring plan helped them increase their operational efficiency and transparency using clinical trial informatics.
Don’t miss out! Register Today!
Andrew Chapman
Senior Director, Informatics
Andrew Chapman MS, PGDip is senior director of product management, a member of the Informatics Leadership Team and is responsible for the commercialization and product management of all external-facing informatics solutions. He joined Covance in early 2016 from CA Technologies where he was responsible for product management for their Linux, storage and test data management products. Andrew received his postgraduate diploma in computer studies (Distinction) from Glasgow Caledonian University and his master’s in computer science (Distinction) from the University of Kent in Canterbury. Prior to his time at CA technologies Andrew spent 12 years at EMC Documentum managing their entire compliance product portfolio. He is the author of a book on the use of enterprise content management systems in highly compliant environments.
Jude Burger
Manager, Risk-Based Monitoring, Eli Lilly and Company
Jude Burger MS, currently manages a team at Eli Lilly dedicated to designing, implementing and evolving a strategy to manage risk in a clinical trial through a risk-based monitoring methodology. He has over 12 years of clinical trial experience, joining Lilly in 2004 as a biostatistician supporting late-phase diabetes. He has also served as a business support consultant for statistical applications and as a central monitoring consultant. Jude received his Bachelor of Arts degree in mathematics from Wartburg College and a Master of Science degree in statistics from Iowa State University. He has been an active member of the TransCelerate Risk-Based Monitoring working group and currently serves as one of its leaders focused on industry engagement.
- Infuse transparency into trial execution using advanced analytical and collaborative tools.
- Mine insights from data across all trials in the portfolio.
- Increase operational efficiency and improve trial outcomes, regardless of who is executing the trial
- Director
- VP
- C Level
- Head of Clinical Operations
- Regulatory
- Compliance
- Informatics
- Procurement
